sharecast

{{ storiesRelated.title }}

THE MOST READ

16:50
Broker tips: Marshalls, Sage, Rolls-Royce, Hyve, Drax, SSE

Analysts at Berenberg raised their target price on paving firm Marshalls from 740.0p to 790.0p on Monday, stating the group was "continuing to deliver".

15:06
FTSE 100 movers: Rolls-Royce retreats; BT top riser

London’s FTSE 100 was down 0.1% at 7,036.38 in afternoon trade on Monday.

11:14
Ryanair sees signs of recovery after record €815m loss

Ryanair on Monday reported a better-than-expected annual loss of €815m due to the Covid-19 pandemic, but added there were signs the recovery had begun and it hoped to break even this year.

15:27
US open: Stocks trade lower following the Street's worst week since February

Wall Street stocks were in the red shortly after the open on Monday following the worst week for major US indices since February.

13:54
Kefi reassures investors after Ethiopian press reports

Ethiopia and Saudi Arabia-focussed exploration and development company Kefi Gold and Copper updated the market following recent press commentary in Ethiopia on Monday.

11:20
High streets lead weekly rise in retail footfall - Springboard

Visits to UK retailers rose slightly last week as shoppers returned to high streets despite the wet weather but made fewer trips to other shopping venues, a survey showed.

10:49
Asia report: Markets mixed as China retail sales disappoint

Markets in Asia closed in a mixed state on Monday, as investors pored through a slew of economic data out of China.

07:29
London pre-open: Stocks to nudge up as restrictions ease further

London stocks were set for a positive open on Monday as Covid-related restrictions in England ease further, but gains are expected to be muted amid concerns about the Indian variant.

16 May
Sunday newspaper round-up: Pfizer, GlaxoSmithKline, Rolls-Royce

Pfizer’s most senior UK executive has criticised the call to forgo patents on Covid vaccines, warning that it would lead to a global shortage of raw materials. Ben Osborn, who leads the American drugs giant in the UK, said an intellectual-property waiver was “not the answer”. “We would see a very rapid short-term impact,” he said. “It could allow any organisation to start procuring some of these basic raw materials across multiple countries.” Osborn, 44, said it could even mean that existing vaccine manufacturers — which include Astra Zeneca and US biotech venture Moderna — would be unable to fulfil their obligations to deliver doses. - Sunday Times

16 May
Sunday share tips: Royal Mail Group, Digital 9 Infrastructure

The Sunday Times's Sabah Meddings told readers to 'buy' shares of Royal Mail Group.